What changed
$TMO — AVOID 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $11.0B | EPS $5.44 vs $5.24 🟢 | Margin 21.8%
💡 Consensus quickly adjusted estimates higher post-beat, so current expectations already reflect the modest upside. The market sees TMO as a steady compounder, not a beat-and-raise story in the near term. No variant view to exploit.
📉 Reward/risk: 1.4:1
🏢 Business Quality: 8 — Leader in life sciences tools, wide moat, but growth has normalized post-COVID./10
📊 Valuation: fair — P/E 22.6 on trailing earnings, in line with 5-year average of ~24 but below peak; DCF suggests limited upside at current levels; EV/EBITDA ~18...
🔮 Catalyst: Q2 2026 earnings release (expected July 2026)
💰 Entry: $492.2, stop $470, target $515
⚖️ Avoid initiating a long position.
📊 Our read: AVOID. Full analysis →
https://stockduty.xyz/s/TMO0625